



(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71

(51) Int Cl.:
C12Q 1/68 (2018.01)

(86) International application number:
PCT/CN2018/073817

(48) Corrigendum issued on:
12.05.2021 Bulletin 2021/19

(87) International publication number:
WO 2019/144275 (01.08.2019 Gazette 2019/31)

(43) Date of publication:
17.03.2021 Bulletin 2021/11

(21) Application number: **18902313.8**

(22) Date of filing: **23.01.2018**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

- **LI, Shuyu**
Beijing 102200 (CN)
- **CHEN, Yanli**
Beijing 102200 (CN)
- **XU, Chunye**
Beijing 102200 (CN)
- **PU, Jue**
Beijing 102200 (CN)

(71) Applicant: **Excellen Medical Technology Co., Ltd.**
Science and Technology Park, Changpin District
Beijing 102200 (CN)

(72) Inventors:
• **LI, Mingming**
Beijing 102200 (CN)

(74) Representative: **Glück Kritzenberger**
Patentanwälte PartGmbB
Hermann-Köhl-Strasse 2a
93049 Regensburg (DE)

(54) **METHOD AND KIT FOR IDENTIFYING LUNG CANCER STATUS**

(57) Provided herein is a method for identifying lung cancer status in a subject comprising: collecting a biological sample from the subject; detecting the methylation level of a biomarker gene in the biological sample, the biomarker gene being one or more selected from the following genes: BCAT1, CDH1, DCLK1, FOXL2, HOXA9, PTGER4, RARB, RASSF1A, Septin9, and SHOX2; and comparing the detected methylation levels with a normal methylation level of a corresponding biomarker gene in the population to determine the lung cancer status in the subject. Also provided herein is a kit for identifying lung cancer status in a subject.




Fig.4